@ARTICLE{
author={Herbst Roy S,...,Andric Zoran G,...,(broj koautora 20)},
year={2021},
title={IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={16},
number={3},
pages={S224-S225},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Herbst Roy S,...,Andric Zoran G,...,(broj koautora 21)},
year={2020},
title={Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110},
journal={SWISS MEDICAL WEEKLY},
volume={},
number={},
pages={31S-32S},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Herbst Roy S,...,Andric Zoran G,...,(broj koautora 22)},
year={2020},
title={Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC},
journal={NEW ENGLAND JOURNAL OF MEDICINE},
volume={383},
number={14},
pages={1328-1339},
document_type={Article},
} 

@ARTICLE{
author={Herbst Roy S,...,Andric Zoran G,...,(broj koautora 20)},
year={2020},
title={Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC},
journal={JOURNAL FOR IMMUNOTHERAPY OF CANCER},
volume={8},
number={},
pages={A1-A1},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Herbst Roy S,...,Andric Zoran G,...,(broj koautora 20)},
year={2019},
title={Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study},
journal={ANNALS OF ONCOLOGY},
volume={30},
number={},
pages={62-63},
document_type={Meeting Abstract},
}